MAPT and Alzheimer disease: The existing literature is predominantly focused on biomarkers of AD pathology, where the main clinical value of their uses is to discriminate between phenotypes that are associated with AD vs. non-AD pathologies, and to measure the advances in underlying biology such as plasma and CSF levels of phosphorylated tau (pTau).